BUD13 Genotype

If your triglycerides creep up despite a clean diet, or if metabolic syndrome runs in your family, part of the answer may be written into your DNA. The BUD13 (Bud Site Selection Protein 13 Homolog) gene sits in a small stretch of chromosome 11 that is closely tied to how your body handles fats in the blood, largely through its neighboring genes.

This test reads the specific letters of your BUD13 sequence to identify variants linked to higher triglyceride levels, dyslipidemia, and metabolic syndrome risk. It is a one-time test that gives you a permanent piece of information about your inherited cardiometabolic wiring. A standard lipid panel can show your current triglyceride level, but it cannot reveal the inherited predisposition that may be shaping those numbers over time.

What This Gene Actually Does

BUD13 codes for a protein that is part of the RES (Retention and Splicing) complex, which helps your cells read and edit genetic instructions correctly. This process is called RNA splicing (the editing step that turns raw genetic messages into usable instructions). Think of it as a quality-control worker on a factory line, making sure the right pieces of each genetic message get assembled before they leave the cell.

BUD13 does not sit alone on the chromosome. It sits inside a tightly clustered group of genes at chromosome 11q23.3 that includes APOA5 (Apolipoprotein A5), APOA1, APOA4, APOC3, SIK3, and ZPR1 (also called ZNF259, the older name for the same gene). Several of these neighbors directly shape how triglycerides move through your bloodstream. Because these genes sit so close together and are often inherited as a block, it can be difficult to tell how much of any single association is driven by BUD13 itself versus its neighbors. Much of the literature treats this as a multi-gene cluster effect, with the strongest individual signals often mapping to APOA5.

Triglyceride and Lipid Risk

The most consistent and well-replicated finding across populations is that variants in this BUD13-containing cluster are tied to higher triglycerides. This has been documented in Korean, Chinese, Taiwanese, Iranian, Indian, Mexican, and Arab cohorts, making it one of the few cardiometabolic genetic signals that shows up reliably across many ancestries.

In a large Taiwanese genome-wide study, BUD13 emerged as one of the key genetic loci associated with severe hypertriglyceridemia, defined as very high triglycerides, alongside APOA5 and other lipid-metabolism genes. A separate Korean study of 12,537 people confirmed that variants in the BUD13-ZNF259-APOA5-APOA1-SIK3 cluster on chromosome 11q23.3 track with elevated plasma triglycerides. Fine-mapping work in Mexican populations has pointed to rs964184, which sits near APOA5, as the strongest individual driver of this association signal.

The effect is not just on triglycerides. A study of Chinese adults found that functional variants in the APOA1/C3/A4/A5-ZPR1-BUD13 cluster were associated with dyslipidemia in a sex-specific way, with one variant (rs5072) linked to hypertriglyceridemia specifically in women. So your genotype in this region is not a universal switch, it interacts with sex and likely other biological context.

Metabolic Syndrome Risk

Metabolic syndrome is a cluster of conditions, abdominal obesity, high blood pressure, high blood sugar, low HDL, and high triglycerides, that together raise your risk of heart disease and diabetes. Variants in the BUD13 region have been repeatedly linked to this cluster, especially the high-triglyceride subtype, though the evidence is not entirely one-sided.

In the Tehran Cardio-metabolic Genetics Study of 5,421 people, statistical analysis of BUD13, ZPR1, and APOA5 variants showed a significant correlation with metabolic syndrome, particularly the version of metabolic syndrome marked by elevated triglycerides. A Taiwanese study of 3,000 adults found that BUD13, along with APOA5, CETP, and LIPA, contributed to metabolic syndrome risk both independently and through interactions with each other and with lifestyle factors.

The picture is not uniform. A case-control study of 3,850 Chinese adults found that BUD13 variants did not increase overall metabolic syndrome risk, although they did affect individual metabolic components like triglycerides and HDL. This null finding is a reminder that the association is real but population- and trait-dependent.

A 10-year longitudinal study of 3,580 adults found that combining the TyG Index (triglyceride-glucose index, a measure of insulin resistance) with BUD13-region genetic markers was numerically better at predicting who would develop metabolic syndrome than either measure alone, although the improvement did not reach statistical significance. The genetic signal may add information your standard labs cannot, but its incremental value is still being worked out.

Coronary Artery Disease

The connection between BUD13 and heart disease is more nuanced than the triglyceride story would suggest. A Chinese Han study of 5,374 people found that variants in the APOA4-APOA5-ZNF259-BUD13 gene cluster were tied to triglyceride levels but did not significantly increase coronary heart disease risk in that population.

In an Indian population study of 1,024 adults, one intronic BUD13 variant (rs17440396) actually showed a protective effect against coronary artery disease, even though variants in the same chromosomal region were linked to elevated LDL and total cholesterol.

This is the kind of finding that looks contradictory until you understand the framework. BUD13 is not a simple good number or bad number gene. The cluster it sits in carries variants that nudge multiple lipid traits at once, and the net effect on disease depends on which other variants you carry, which population you belong to, and which clinical outcome you are looking at. The triglyceride association is consistent. The downstream cardiovascular effect is more variable, which is why your BUD13 result is useful alongside other risk markers rather than as a standalone verdict.

Cognitive Health Signal

A 2025 study of 5,111 rural Indians used genetic markers in the APOA4-APOA5-ZPR1-BUD13 locus, among others, to link cardiometabolic traits to cognitive function, suggesting that the same gene cluster shaping your blood fats may also influence brain aging through cardiometabolic pathways. This is early evidence, not a screening tool, but it points to why getting a handle on your lipid-related genetic risk may matter beyond the heart.

What This Test Cannot Tell You

BUD13 genotyping is currently a research and exploratory marker. There are no standardized clinical cutpoints, no guideline-recommended thresholds, and no validated risk calculators that turn your genotype into a number you can plug into a heart attack prediction tool. The associations are real and replicated, but the test does not yet carry the interpretive weight of an established clinical marker like LDL or ApoB.

What it can do is give you an early, durable piece of information about your inherited tendency toward higher triglycerides and metabolic syndrome. That is useful if you are trying to understand why your numbers behave the way they do, or if you want to know which risks to monitor more closely.

One Time Result, Lifelong Use

This is a once-in-a-lifetime test. Your BUD13 sequence does not change with age, diet, exercise, or any medication. You take it once and the result stays with you. There is no retesting cadence to follow.

The value of the test comes from how you use the result going forward, not from repeating it. If your genotype shows elevated risk for high triglycerides or metabolic syndrome, the actionable response is to track the downstream phenotype, your actual lipid panel, fasting glucose, and metabolic syndrome markers, more aggressively over time. A baseline lipid panel, retested every 6 to 12 months if you are making lifestyle changes, and at least annually thereafter, becomes the practical follow-through.

What Genetic Testing Can And Cannot Detect

A few limits of genetic testing are worth knowing before you interpret your result.

• Variant panel coverage: this assay only detects the specific BUD13 variants it is designed to read. A negative result does not rule out other rare variants in the same gene that the panel does not cover.
• Cluster-level signal: many of the strongest triglyceride associations in this region map to APOA5 and ZPR1 rather than BUD13 itself, and the genes are often inherited together. A BUD13 result is best read as a marker of risk in the broader 11q23.3 cluster, not as a standalone gene effect.
• Ethnic-specific allele frequencies: most BUD13 evidence comes from East Asian, South Asian, Middle Eastern, and Latin American populations. The clinical meaning of a variant can shift by ancestry, and your result should be interpreted with your background in mind.
• Inherited tendency is not destiny: carrying a risk variant does not mean you will develop high triglycerides or metabolic syndrome. It means your inherited starting point tilts in that direction, and lifestyle factors still carry significant weight.
• Clinical-grade vs direct-to-consumer: consumer ancestry tests sometimes report SNPs in this region. A clinical-grade assay is more reliable for interpretation, and if your consumer test flagged a BUD13 variant, confirming it with a clinical test is reasonable.

What To Do If You Carry A Risk Variant

An elevated-risk BUD13 result is not a diagnosis. It is a flag that says, watch your lipid and metabolic numbers carefully. The practical pathway is to pair the genetic result with phenotype testing, your actual blood fats and metabolic health, and let those numbers drive intervention decisions.

• Order a lipid panel with triglycerides if you have not in the last year, and pay particular attention to triglyceride and HDL values.
• Add a fasting glucose, HbA1c, and insulin to screen for the metabolic syndrome cluster that variants in this region are most tightly linked to.
• Consider an NMR lipoprofile or ApoB to get a more complete picture of cardiovascular risk than triglycerides alone provide.
• Talk to a lipidologist or cardiologist if your triglycerides are persistently elevated alongside your genetic risk, since the combination is more clinically meaningful than either signal alone.
• Share the result with biological family: siblings, children, and parents share roughly half your DNA, so a meaningful BUD13 finding may apply to them too.

How To Read Your Result

A BUD13 result will report your genotype at one or more positions in the gene. The lab will typically flag whether your specific variant is associated with elevated risk based on published research. Because there are no universally agreed-on clinical cutpoints, the interpretation depends on which variant you carry, your ancestry, and how the rest of your lipid and metabolic profile looks. Treat the result as one piece of a larger picture, not a verdict.